The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•15 May 2026•

1 min read

Barclays Raises Progyny Target Price Following Record Q1 Revenue Beat

Key Facts

1Barclays raised its price target for PGNY to $27.00 while maintaining an Overweight rating.

2Progyny reported Q1 2026 earnings of $0.50 per share, beating the consensus estimate of $0.44.

3The company posted record revenue of $328.5 million, surpassing the $324.04 million from the same quarter last year.

Barclays has raised its price target for Progyny (PGNY) to $27.00 while maintaining an Overweight rating on the stock. The adjustment follows the company's Q1 2026 earnings report, which showed earnings of $0.50 per share, surpassing the consensus estimate of $0.44. Additionally, the company posted record revenue of $328.5 million, up from $324.04 million in the same period last year.

The upgrade highlights Progyny's consistent performance, having exceeded analyst estimates for four consecutive quarters driven by robust demand for fertility solutions and active share repurchases. In the broader healthcare context, Progyny's growth stands out against peers such as DaVita (DVA) and Globus Medical (GMED), which have seen varied price action per market data, as PGNY continues to capture market share in specialized benefits management.

As of the close on May 15, 2026, PGNY shares reflect the positive sentiment from the earnings beat. Investors are now looking ahead to upcoming macroeconomic catalysts, including U.S. Existing Home Sales and inflation data scheduled for release in mid-May, which could impact broader consumer discretionary spending and healthcare sector valuations.